Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. Sparano, J. A., Gray, R., Wood, W. C., Makower, D. F., Lively, T. G., Saphner, T., Keane, M. M., Gomez, H., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D., Brufsky, A., Goetz, M. P., Hayes, D. F., Dees, E., Pritchard, K. I., Geyer, C. E., Olson, J. A., Sledge, G. W. AMER SOC CLINICAL ONCOLOGY. 2018
View details for Web of Science ID 000443284700002